Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aspirin study

This article was originally published in The Tan Sheet

Executive Summary

"Aspirin resistance" findings in study of high-risk cardiovascular patients may have resulted from poor aspirin regimen compliance, Bayer says in response to trial published in March 26 Circulation. Conducted by John Eikelboom, University of Western Australia, et al., study looked at 488 individuals with potential aspirin resistance out of 5,529 subjects enrolled in Heart Outcomes Prevention Evaluation Study. Such individuals may "benefit from additional antiplatelet therapies or treatments that more effectively block in vivo thromboxane production or activity," researchers say...

Related Content

“Aspirin Resistance” Clinical Significance Challenged In Circulation Report





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts